Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
18
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
biotech
fda
national top stories
drugs
alnylam pharmaceuticals
san francisco blog main
deals
new york blog main
patisiran
rna interference
san diego blog main
avapritinib
blueprint medicines
hereditary transthyretin amyloidosis
new york top stories
onpattro
rare disease drugs
roche
san diego top stories
san francisco top stories
akcea therapeutics
alexion pharmaceuticals
aminolevulinic acid
cancer
dyne therapeutics
eli lilly
european medicines agency
gene therapy
genentech
givosiran
inotersen
investing
life science
medullary thyroid cancer
What
drug
18
×
fda
medicines
medicine
approval
pharmaceuticals
therapeutics
alnylam
genetic
ipo
new
rnai
approved
blueprint
cancer
data
interference
muscle
rna
seek
ago
approves
biotech
candidate
company
depression
developing
disease
diseases
dyne
eye
filing
gene
history
hits
lead
long
medical
million
ok
Language
unset
Current search:
boston
×
drug
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
CVS Health Expands Delivery, as Pharmacies Try to Keep Amazon at Bay